News/ News/ Oncology Lilly bolts on cancer bispecifics with $1.6bn Merus alliance Phil Taylor bispecific antibody, Eli Lilly, immuno-oncology, Merus, Oncology, partnering 0 Comment Always a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share X Lilly bolts on cancer bispecifics with $1.6bn Merus alliance https://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
bispecific antibody, Eli Lilly, immuno-oncology, Merus, Oncology, partnering
0 Comment
